Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective non-randomized study of bortezomib-based triplets in newly diagnosed multiple myeloma
ChiCTR1900025577Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bortezomib, lenalidomide, cyclophosphamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Overall response rate, Complete response rate and 1 more. Started Sep 2019; status: completed.
02
Drugs
bortezomiblenalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900025577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025577.